RxDoctor Payments Data

Sameer Chaudhari, MD

Cardiovascular Disease · Charlotte, NCNPI 1467680918

Payments from drug & device makers

$6,748in general payments, 2019–2025

Across 198 payments — averaging $34.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Amgen$780
  • Novartis$650
  • Boston Scientific$355
  • Johnson & Johnson$290
  • E.r. Squibb & Sons, L.L.C.$246
  • plus $2K from 19 others

What the payments were for

  • Travel & lodging$1,88928%
  • Food & beverage$4,75470%
  • Education$1052%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,748 in reported general payments places this provider in the 65th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$152,275
Medicare patients
845
Services billed
2,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban314$285,452
Repatha SureclickEvolocumab113$105,328
XareltoRivaroxaban75$88,577
EntrestoSacubitril/Valsartan83$70,663
JardianceEmpagliflozin27$18,803
Praluent PenAlirocumab24$17,902
Metoprolol Succinate451$3,553
Rosuvastatin Calcium422$3,204
Diltiazem 24hr Er (Cd)Diltiazem Hcl103$2,794
Flecainide Acetate106$2,663
Atorvastatin Calcium237$1,883
Ranolazine ErRanolazine23$1,801
Torsemide83$1,631
Potassium Chloride114$1,480
Amiodarone Hcl38$1,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$130$285,452314 claims
Johnson & JohnsonXarelto$290$88,57775 claims
NovartisEntresto$650$70,66383 claims
Boehringer IngelheimJardiance$160$18,80327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →